HopeStage
Back to all studies
CompletedNCT02285504

SAGE-547 for Severe Postpartum Depression

About this titleRead the official source — NCT02285504

This study evaluated the safety and effectiveness of SAGE-547 for people with depression.

Medication studyAges 18–45United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of SAGE-547 for people with depression.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Listed locations
Chapel HillSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 7, 2015
Recruitment status
Completed
Enrollment listed in the registry
4
Sponsor
Supernus Pharmaceuticals, Inc.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT02285504
Official title
Show the full official title

An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Chapel Hill

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of SAGE-547 for people with depression.

Who is behind this study?

The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including SAGE-547.

Who was this study for?

This study was for people with depression. Listed age limits: 18 years to 45 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies